The current analysis showed consistent reductions with semaglutide in the risk of MACE versus placebo across baseline eGFR and UACR subgroups, which is in line with a meta-analysis that evaluated CVOTs showing that GLP-1RAs reduced the risk of MACE versus placebo, regardless of baseline eGFR [7]
USA 110 , 90669071 (2013)
Ahmed, Z., Wang, Y., Ahmad, A., Khan, S
DSIP 5mg total per bottle 62.5 mcg 80 sprays/bottle 10mL bottle Third-party tested Qalitex Identity confirmed Certificate of Analysis Tested by Qalitex 07/17/2026 Key Ingredients A nine-amino acid neuropeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) studied for its effects on sleep architecture, delta wave EEG patterns, and neuroendocrine stress response modulation